Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

References

• Komrokji RS. Current state of the art: management of higher risk myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2016;16:S39–S43.
   PubMed Web of Science ®Google Scholar
• Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–1542.
   PubMed Web of Science ®Google Scholar
• Disperati P, Ichim CV, Tkachuk D, et al. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology. Leuk Res. 2006;30:233–239.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• NCCN.org [Internet]. Fort Washington, PA: NCCN. Myelodysplastic syndromes. V.2.2017; [cited 2017 Apr 17]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf.
   Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–1803.
   PubMed Web of Science ®Google Scholar
• Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29:1987–1996.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429–2440.
   PubMed Web of Science ®Google Scholar
• Lawrence LW. Refractory anemia and the myelodysplastic syndromes. Clin Lab Sci. 2004;17:178–186.
   PubMedGoogle Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood. 1998;91:1100]. Blood. 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Greenberg PL. The myelodysplastic syndromes. In: Hoffman R, Benz E, Shattil S, Cohen H, eds. Hematology: basic principles and practice. 3rd ed. New York, NY: Churchill Livingstone; 2000. p. 1106–1129.
   Google Scholar
• Brechignac S, Hellstrom LE, Bowen DT, et al. Quality of life and economic impact of red blood cell (RBC) transfusions on patients with myelodysplastic syndromes (MDS) [abstract 4716]. Blood. 2004;104:263b.
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E. Management of anemia associated with myelodysplastic syndrome. Semin Hematol. 2005;42:S10–S13.
   PubMed Web of Science ®Google Scholar
• DeZern AE, Binder G, Rizvi S, et al. Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes. Leuk Lymphoma. 2017;58:2649–2656.
   PubMed Web of Science ®Google Scholar
• Gupta P, LeRoy SC, Luikart SD, et al. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res. 1999;23:953–959.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Anderson JE, Ganser A, et al. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica. 1998;83:910–935.
   PubMed Web of Science ®Google Scholar
• Pomeroy C, Oken MM, Rydell RE, et al. Infection in the myelodysplastic syndromes. Am J Med. 1991;90:338–344.
   PubMed Web of Science ®Google Scholar
• Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27:1850–1856.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Paolo S, Cabrero M, et al. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017;92:351–358.
   PubMed Web of Science ®Google Scholar
• Bernal T, Martinez CP, Sánchez GJ, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29:1875–1881.
   PubMed Web of Science ®Google Scholar
• Dinmohamed AG, van Norden Y, Visser O, et al. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Leukemia. 2015;29:2449–2451.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603.
   PubMed Web of Science ®Google Scholar
• Harnan S, Ren S, Gomersall T, et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis. Acta Haematol. 2016;136:23–42.
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO classification and WPSS predict post-transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 2008;112:895–902.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96:1433–1440.
   PubMed Web of Science ®Google Scholar
• Triantafylldis I, Ciobanu A, Stanca O, et al. Prognostic factors in myelodysplastic syndromes. Maedica. 2012;7:295–302.
   PubMedGoogle Scholar